Alphavax

The alphavaccine technology is based on AlphaVax’s proprietary replicon vector platform derived from attenuated strains of the alphavirus, Venezuelan equine encephalitis (VEE) virus. Industry interest in the alphavaccine technology has increased as vaccine candidates move through the development pipeline.

Overview Structured Data Issues Contributors

Is a

Company attributes

Industry

Biomanufacturing

Infectious disease (medical specialty)

Internal medicine

...

Location

Research Triangle Park

CEO

Steven C. Mizell

Number of Employees (Ranges)

51 – 200

Email Address

Phone Number

DUNS Number

48731504

Patents Assigned (Count)

1

No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more companies like Alphavax

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.